Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model

Next Previous
Trial Profile

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzaplatovir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Aviragen Therapeutics

Most Recent Events

  • 02 Feb 2017 According to an Aviragen Therapeutics media release, safety results from this trial along with the other clinical data will form the basis for the interaction with the FDA to discuss lifting the clinical hold on BTA585s Investigational New Drug application.
  • 01 Feb 2017 According to an Aviragen Therapeutics media release, company is planning to analyse the full data and report the plan for this program in the second quarter of 2017.
  • 01 Feb 2017 Results published in an Aviragen Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top